Xcenda Leader Provides Insight on Biosimilars for Payers and Pharma

Managing Director Allen Lising of Xcenda’s FormularyDecisions shared his thoughts on biosimilars. He notes that when it comes to the biosimilar development pipeline, payers are starting to require data as much as 18 months before approval by the FDA. At the same time, biosimilar manufacturers are providing a larger amount of data than before, even if not required, to improve their market access. Lising discusses Biosimilars Hub, a streamlined solution that compiles data one a single location. The platform can also integrate third-party reports from the Institute for Clinical and Economic Review.

Lising remarks, “So, in our platform, it’s FDA compliant for secure requests,” adding, “And specific to biosimilars, we saw a gap in the need for biosimilar information and we started to add biosimilar products to the platform. Over the past couple of years, we saw that we need to go beyond that.” Read more here.

(Source: Tony Hagen, American Journal of Managed Care – The Center for Biosimilars, 4/22/21)